Pathophysiological role of growth factors in diabetic kidney disease: Focus on innovative therapy

被引：4

作者：

Flyvbjerg, A ^{[1
]}

Hill, C

Logan, A

机构：

[1] Univ Aarhus, Aarhus Kommune Hosp, Med Res Lab M, DK-8000 Aarhus C, Denmark

[2] Univ Aarhus, Aarhus Kommune Hosp, Med Dept Diabet & Endocrinol M, DK-8000 Aarhus C, Denmark

[3] Univ Birmingham, Dept Med, Birmingham B15 2TH, W Midlands, England

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 1999年 / 10卷 / 07期

关键词：

D O I：

10.1016/S1043-2760(99)00167-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Various growth factors have been proposed to be players in the development of diabetic microvascular complications. In particular the growth hormone/insulin-like growth factor system and the transforming growth factor beta system have measurable effects on the development of diabetic kidney disease through a complex intrarenal system. Recent findings indicating that these growth factors might be responsible for early renal changes in diabetes have provided insight into processes that might be relevant to the future development of new drugs useful in the treatment of diabetic kidney disease.

引用

页码：267 / 272

页数：6

共 44 条

[1] A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin [J].

Chen, NY ;

Chen, WY ;

Kopchick, JJ .

ENDOCRINOLOGY, 1996, 137 (11) :5163-5165

[2] EFFECTS OF STREPTOZOTOCIN TREATMENT IN GROWTH-HORMONE (GH) AND GH ANTAGONIST TRANSGENIC MICE [J].

CHEN, NY ;

CHEN, WY ;

BELLUSH, L ;

YANG, CW ;

STRIKER, LJ ;

STRIKER, GE ;

KOPCHICK, JJ .

ENDOCRINOLOGY, 1995, 136 (02) :660-667

[3] Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes [J].

Cummings, EA ;

Sochett, EB ;

Dekker, MG ;

Lawson, ML ;

Daneman, D .

DIABETES, 1998, 47 (08) :1341-1346

[4] INTERNATIONAL-SYMPOSIUM ON GLUCOSE-METABOLISM AND GROWTH-FACTORS - MAINZ, GERMANY, JANUARY 20-22, 1995 - PREFACE [J].

FLYVBJERG, A ;

ALBERTI, KGMM ;

FROESCH, ER ;

DEMEYTS, P ;

VONZURMUHLEN, A ;

ORSKOV, H .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (10) :1-1

[5] STIMULATION OF HEPATIC INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-1 AND PROTEIN-3 GENE-EXPRESSION BY OCTREOTIDE IN RATS [J].

FLYVBJERG, A ;

SCHULLER, AGP ;

VANNECK, JW ;

GROFFEN, C ;

ORSKOV, H ;

DROP, SLS .

JOURNAL OF ENDOCRINOLOGY, 1995, 147 (03) :545-551

[6] OCTREOTIDE ADMINISTRATION IN DIABETIC RATS - EFFECTS ON RENAL HYPERTROPHY AND URINARY ALBUMIN EXCRETION [J].

FLYVBJERG, A ;

MARSHALL, SM ;

FRYSTYK, J ;

HANSEN, KW ;

HARRIS, AG ;

ORSKOV, H .

KIDNEY INTERNATIONAL, 1992, 41 (04) :805-812

[7] Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice [J].

Flyvbjerg, A ;

Bennett, WF ;

Rasch, R ;

Kopchick, JJ ;

Scarlett, JA .

DIABETES, 1999, 48 (02) :377-382

[8]

FLYVBJERG A, 1988, DIABETOLOGIA, V31, P310

[9] SOMATOSTATIN ANALOG ADMINISTRATION PREVENTS INCREASE IN KIDNEY SOMATOMEDIN-C AND INITIAL RENAL GROWTH IN DIABETIC AND UNINEPHRECTOMIZED RATS [J].

FLYVBJERG, A ;

FRYSTYK, J ;

THORLACIUSUSSING, O ;

ORSKOV, H .

DIABETOLOGIA, 1989, 32 (04) :261-265

[10] KIDNEY IGF-I AND RENAL HYPERTROPHY IN GH-DEFICIENT DIABETIC DWARF RATS [J].

FLYVBJERG, A ;

FRYSTYK, J ;

OSTERBY, R ;

ORSKOV, H .

AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 262 (06) :E956-E962

← 1 2 3 4 5 →